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E-mail address: birgera@umdnj.edu (R.B. Birge).Since their discovery as cellular counterparts of viral oncogenes more than two decades ago, enor-
mous progress has beenmade in unraveling the complex regulatory pathways of signal transduction
initiated by the Crk family of proteins. New structural and biochemical studies have uncovered
novel insights into both negative and positive regulation of Crk mediated by its atypical carboxyl-
terminal SH3 domain (SH3C). Moreover, SH3C is tyrosine phosphorylated by receptor tyrosine
kinases and non-receptor tyrosine kinases, thereby permitting assemblages of other SH2/PTB
domain containing proteins. Such non-canonical signaling by the Crk SH3C reveals new regulatory
strategies for adaptor proteins.
 2012 Federation of European Biochemical Societies. Published by Elsevier B.V.Named for their ability to elevate cellular tyrosine phosphoryla-
tion and transform primary chicken embryo ﬁbroblasts (CEFs) [1],
CT10 regulator of kinase (Crk) is the prototypical member of a class
of Src Homology-2 (SH2) and Src Homology-3 (SH3) domain-con-
taining proteins that lack intrinsic enzymatic activity but instead
function to promote protein–protein interactions [2,3]. Over the
past two decades, enormous progress in our understanding of sig-
nal transduction has emerged from studies on Crk. The canonical
signaling pathway, deﬁned by recognition of speciﬁc phosphotyro-
sine motifs by the SH2 domain (in the context of p-Tyr.X.X.Pro) [4]
and Polyproline Type II motifs by the N-terminal SH3 domain {in
the context of Pro. X. X. Pro. X. (Lys/Arg)} [5], identiﬁed Crk as a
connector between Receptor Tyrosine Kinases (RTKs) and/or their
substrates and GTPase effector pathways (Fig. 1). Along with ef-
forts on Grb2 [6], these insights were instrumental in deﬁning
missing links between integrins and/or tyrosine phosphorylated
growth factor receptors and downstream effector pathways that
regulate growth and differentiation, and also more generally for
deﬁning elements of modular domains in signaling. In recent years,
new layers of regulation for Crk have emerged, pointing to not only
unusual levels of auto-inhibition mediated by its atypical carboxyl-
terminal SH3 domain, but also unexpected features of SH3 domain
signaling that activate non-canonical pathways.
CrkII and CrkL each contain an atypical C-terminal SH3 domain
(SH3C), deﬁned by its inability to bind to Polyproline Type II (PPII)
motifs [7,22]. In both proteins, the atypical SH3 domain retainsal Societies. Published by Elseviercore structural characteristics of SH3 domains, consisting of a
ﬁve-stranded b-barrel which forms the standard SH3 fold. How-
ever, the aromatic amino acids – F141, W169, Y186 which line
the canonical PPII binding pocket on the Crk SH3N and are con-
served in conventional SH3 domains, are replaced by polar resi-
dues – Q244, Q274 and H290 on the SH3C surface (Fig. 2),
thereby rationalizing the drastically reduced afﬁnity of this domain
for proline rich sequences.
The carboxyl-terminal region of Crk is considered inhibitory,
since it contains elements that constrain binding to the N-terminal
SH2 and SH3 domains. Phosphorylation at Tyr221 in the inter-SH3
linker region facilitates binding to the Crk SH2 in cis to form a
closed structure that prevents the SH2 domain from binding in
trans to tyrosine phosphorylated proteins [8–10] (Fig. 3a). Another
layer of negative regulation appears to operate to prevent binding
in trans to the SH3N. This is mediated via cis–trans isomerization
about the Gly237-Pro238 peptide bond (in gallus CrkII) [11,12].
Intriguingly, only the cis conformer adopts an autoinhibited state
whereby the hydrophobic surface of the canonical PPII binding site
on the SH3N (composed of Phe142, Phe144, Trp170, Tyr187,
Pro184 and Pro186) is occupied by Pro238, Phe239 and Ile270 of
the SH3C in a manner similar to a PPII peptide. This arrangement
in essence allows the SH3C to act as a reversible lid that caps the
SH3N from binding PPII ligands.
In contrast, the trans conformer adopts an open state where the
PPII binding site on the SH3N is not occluded by the SH3C as
Phe239 undergoes a major shift to the interior of the SH3C and
Ile270 moves to face the center. In the ligand unbound form, the
cis conformer is favored thereby resulting in 90% of the SH3N-lin-B.V. Open access under CC BY-NC-ND license. 
Fig. 1. Overview of the Crk family of adaptor proteins. Domain organization and
binding preferences of the Crk family of adaptor proteins. Note that the C-terminal
SH3 domain is atypical in that it does not recognize PPII motifs.
2616 G. Sriram, R.B. Birge / FEBS Letters 586 (2012) 2615–2618ker-SH3C molecules to be in the auto-inhibited state (Fig. 3b).
While CypA can affect the kinetics of conversion between the
auto-inhibited and open state by catalyzing the inter-conversion
between the cis and trans conformers, CypA does not appear to
be the driving force that regulates the ratio of these conformers. Li-
gand binding to the subset of molecules in the open state is pre-
dicted to shift the equilibrium towards the open state and
‘‘activate’’ Crk SH3N mediated signaling. This is likely mediated
by the cellular localization and availability of the natively ex-
pressed proteins with PPII motifs.
Adding to the complexity, the sequence around Pro238 is not
conserved in human Crk and it remains to be determined if cis–
trans isomerization operates to negatively regulate the human
Crk SH3N. However, the solution structure of human Crk has re-
vealed the existence of a modiﬁed mode of auto-inhibition con-
ferred by the linker in between the SH3 domains [10], the same
general region identiﬁed to control cis–trans isomerization in the
chicken Crk protein (Fig. 3c). Residues 224–237, called the Inter
– SH3 core (ISC), form contacts with the SH2 and the SH3 domains
to assemble CrkII into a compact structure. Mutation of prolines
and hydrophobic residues in the ISC to glycine and serine respec-
tively, enhances the afﬁnity of the SH3N for a PPII peptide in the
context of full length CrkII. Also, mutation of W275 in the SH3C,Fig. 2. Comparison of the conventional and atypical SH3 domains in Crk. The atypical C-t
domain. Note that the hydrophobic residues lining the canonical PPII binding site on thwhich would disrupt the core fold of this domain, also enhances
the afﬁnity of the SH3N suggesting that the structural integrity
of the SH3C is required to maintain crucial contacts with the ISC
for SH3N auto-inhibition. Although the mode of auto-inhibition
of the SH3N may not be conserved between chicken and human
Crk, the function of the linker and the atypical SH3 to regulate
SH3N mediated signaling nonetheless appears to be maintained.
This notion that assembly of inter-domain interactions has sig-
niﬁcant functional consequences is further highlighted by insights
into the structure of CrkL, a closely related protein to CrkII. These
studies have brought to light distinct features that are regulated
by structural organization of the SH2 and SH3 domains [22].
Although there is a high level of conservation within the modular
domains between the two proteins and the binding preferences
are very similar, the linker and the SH3C domain are organized
very differently in CrkL compared to CrkII (Fig. 3d). While in CrkII,
the linker and the SH3C have been shown to play a key role in
auto-inhibition of the SH3N, there appears to be no such contribu-
tion by the respective elements in CrkL. Also strikingly, the SH2
and the SH3N interact directly by predominantly polar contacts
to occlude the binding pocket of the SH2 domain in CrkL whereas
such occlusion of the SH2 binding pocket is not observed in CrkII.
Interestingly, phosphorylation at the negative regulatory tyrosine
207 in CrkL that results in binding to its own SH2 does not reduce
the afﬁnity of the SH3N domain for its ligands. In contrast, the CrkII
SH3N has been shown to be partially occluded upon phosphoryla-
tion at Y221 and binding to its own SH2 domain. These new in-
sights have impressed upon the idea that although the typical
folds of these modular domains determine speciﬁcity of ligand rec-
ognition, the linkers have evolved to bear key regulatory features
that determine the binding afﬁnities of these modular domains
for their respective ligands in the context of full length proteins.
While the atypical SH3C domain is intrinsically negative regula-
tory in nature, new data also suggests that it can have an afﬁrma-
tive role in signaling courtesy of a non-canonical role mediated by
tyrosine phosphorylation. The Crk SH3C, in contrast to conven-
tional SH3 domains, has a tyrosine residue in the RT-loop structure.
Recently, this residue, Y251, was shown to be phosphorylated by
Abl and downstream of EGFR in addition to the negative regulatory
tyrosine 221 [13]. Phosphorylation at Y251 enhances Abl activation
by virtue of binding to the Abl SH2 domain and unclamping theerminal SH3 domain is presented side by side with the conventional N-terminal SH3
e SH3N are replaced by polar residues on the SH3C.
Fig. 3. Modes of auto-inhibition in Crk II. (A) Phosphorylation at Y221 on the linker between the Crk SH3 domains results in binding to the Crk SH2 in cis thereby resulting in
the formation of a closed structure and disassembly of Crk SH2-mediated complexes. (B) In gallus CrkII, binding of PPII ligands to the SH3N is negatively regulated by cis–trans
isomerization about the Gly237-Pro238 peptide bond whereby, the SH3C masks the PPII binding site on the SH3N in the cis conformation but the PPII binding site is not
occluded by the SH3C in the trans conformation. (C) In human CrkII, the linker assembles individual domains by means of an inter-SH3 core (ISC, in bold) in a way that packs
the SH3N which results in reduced afﬁnity for PPII ligands in the context of full length CrkII compared to the isolated domain. The interactions of the SH3C with ISC stabilize
the core. (D) Contrastingly in CrkL, the SH2 and the SH3N domains interact directly with each other whereby the phosphotyrosine motif binding pocket of the SH2 is occluded
by the SH3N. However, neither the linker nor the SH3C domain occludes the PPII binding site on the SH3N.
Fig. 4. Binary switch mechanism of signaling by Crk II via tyrosine phosphorylation. Downstream of activated receptor tyrosine kinases (RTK), Crk is recruited to speciﬁc
tyrosine phosphorylation sites at the plasma membrane via its SH2 domain and in turn recruits downstream effectors such as DOCK180, C3G or Abl to the membrane via
binding to PPII motifs through its SH3N domain. Recent evidence that Crk is phosphorylated at Y251 in addition to Y221 downstream of EGFR suggests that tyrosine
phosphorylation at these two sites could now switch localization and/or signaling from the SH2–SH3N axis to an SH3C mediated pathway as indicated. GF stands for growth
factor.
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provides binding sites for SH2/PTB domain containing proteins
thereby predicting non-canonical signaling pathways. Such a mod-iﬁcation confers a gain of function that immediately highlights an
interesting scenario involving a binary switch mechanism (Fig. 4).
By this mechanism, phosphorylation at Y221 on Crk would result
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the SH2–SH3N axis while simultaneous phosphorylation at Y251
would re-localize Crk by virtue of binding to another SH2/PTB do-
main containing protein thereby switching to an SH3C mediated
signaling pathway. This scenario also predicts that upon receptor
tyrosine kinase activation (such as EGFR), localization of Crk would
be elegantly ‘switched’ by tyrosine phosphorylation at Y221 and
Y251 from being SH2-dependent to being SH3C dependent for an
appropriate biological response such as cell migration towards a
growth factor gradient.
Although post-translational modiﬁcation of conventional SH3
domains by tyrosine phosphorylation has been documented, for
example for Btk, Abl and recently for the CAS/BCAR1 SH3 domain,
in contrast to the Crk SH3C, this occurs on the conserved tyrosine
in the hydrophobic ligand binding pocket and thereby reduces the
afﬁnity of the SH3 domain for its ligands [14–18]. The SH3 domain
of CAS/BCAR1, a focal adhesion protein shown to be associated
with resistance to anti-estrogens in breast cancer, is phosphory-
lated on this tyrosine in Src-transformed cells [19]. Phosphoryla-
tion on this tyrosine reduced association with FAK and PTP-PEST,
decreased cell spreading and enhanced cell migration [18], imply-
ing this modiﬁcation within the CAS SH3 domain likely serves as a
switch to promote turnover of focal adhesions. The unifying theme
that emerges from the above ﬁndings is that SH3 domain–ligand
complexes can be turned over by tyrosine phosphorylation of the
SH3 binding pocket thereby permitting re-assembly at a different
location in the case of scaffold proteins. Afﬁrmative recruitment
of SH2 domains reﬂects another variation in this theme, where this
would allow phosphorylated Crk to re-engage signals when p-
Tyr221 is occupied intra-molecularly with its SH2 domain.
The duplication of SH3 domains in Crk and the divergence in
biological function of the SH3C is reminiscent of the duplication
in other simple adaptor proteins such as Grb2 and Nck. The Grb2
SH3C has been shown to recognize a sequence with an RxxK core
binding motif in Gab2 which can be embedded within a PPII motif
[20,21]. Although this is removed from a conventional SH3 binding
sequence, the Grb2 SH3C retains the hydrophobic amino acids that
line the canonical PPII binding pocket, and has therefore not di-
verged as much as the Crk SH3C from conventional SH3 domains.
It is likely that a unique combination of an atypical SH3 domain
and a typical SH3 domain have co-evolved for synergistic and
cooperative signaling, for example as seen for the capping of the
SH3C to the SH3N in Crk II. It should be of interest to assign other
co-operative functions where combination of one conventional
SH3 and one atypical SH3 exist in single proteins.
The emergence of functional insight into the role of the atypical
SH3 domain in Crk provides new details into the biology of Crk
proteins, particularly in the differential regulation of Crk I and
Crk II and also in deﬁning species speciﬁc variations in regulation.
Crk signaling is often upregulated in cancers because of increasedcoupling with overexpressed or deregulated growth factor recep-
tors and non-receptor tyrosine kinases. Further interrogation of
the Crk family will likely provide additional information about
their modes of regulation as well as their contributions to disease
and potential drug targets.
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